Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apitolisib + abiraterone
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Apitolisib + abiraterone is an investigational combination therapy used primarily in clinical trials for metastatic castration-resistant prostate cancer (mCRPC), usually in conjunction with prednisone. Apitolisib (GDC-0980) is a highly selective dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), which blocks both PI3K-alpha and mTOR pathways, impeding cell growth and survival signaling. Abiraterone (CB7630, Zytiga) is a potent and irreversible inhibitor of CYP17A1, blocking androgen biosynthesis and thereby suppressing androgen receptor (AR) signaling that drives prostate cancer progression. The combination is designed to disrupt compensatory signaling between the androgen receptor pathway and the PI3K/mTOR pathway, aiming to overcome resistance mechanisms in advanced prostate cancer.
- Other names
- apitolisib + abirateroneapitolisibGDC-0980GDC0980GDC 0980abirateroneCB7630CB-7630CB 7630
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on apitolisib + abiraterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apitolisib + abiraterone.